BIOCON:NSE
Biocon Ltd
352,00 ₹
arrow_upward
+0,40%(+1,40) 1D
15. okt., 15:30:00 GMT +5.30 · INR
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za BIOCON …
Odpri
354,00 ₹
Visoka
356,35 ₹
Nizka
350,00 ₹
Tržna kapitalizacija
421,18 mrd.
Povprečni promet
3,10 mio.
Promet
1,73 mio.
Dividenda
0,14 %
Četrtletna dividenda
0,12 ₹
Prvi trgovalni dan brez upravičenja do dividende
3. jul. 2026
Razmerje med ceno delnice in čistim dobičkom
104,21
52-tedenski najvišji tečaj
447,15 ₹
52-tedenski najnižji tečaj
337,70 ₹
Čisti dobiček na delnico
3,38 ₹
Št. izdanih delnic
600,00 mio.
Št. zaposlenih
16 tis.
Odpri
354,00 ₹
Visoka
356,35 ₹
Nizka
350,00 ₹
Tržna kapitalizacija
421,18 mrd.
Povprečni promet
3,10 mio.
Promet
1,73 mio.
Dividenda
0,14 %
Četrtletna dividenda
0,12 ₹
Prvi trgovalni dan brez upravičenja do dividende
3. jul. 2026
Razmerje med ceno delnice in čistim dobičkom
104,21
52-tedenski najvišji tečaj
447,15 ₹
52-tedenski najnižji tečaj
337,70 ₹
Čisti dobiček na delnico
3,38 ₹
Št. izdanih delnic
600,00 mio.
Št. zaposlenih
16 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
TipRanks
·
pred 1 dnevom
Biocon Secures Global Deal with Genentech to Launch Pebrilzo Biosimilar
Profil
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Vizitka: Biocon Ltd
Generalni direktorShreehas P Tambe
Št. zaposlenih16,4 tis.
Ustanovljeno29. nov. 1978
SedežBangalore, Karnataka, Indija
Sektor-
Spletno mestobiocon.com